作者
Dapeng Li, Robert J Edwards, Kartik Manne, David R Martinez, Alexandra Schäfer, S Munir Alam, Kevin Wiehe, Xiaozhi Lu, Robert Parks, Laura L Sutherland, Thomas H Oguin III, Charlene McDanal, Lautaro G Perez, Katayoun Mansouri, Sophie MC Gobeil, Katarzyna Janowska, Victoria Stalls, Megan Kopp, Fangping Cai, Esther Lee, Andrew Foulger, Giovanna E Hernandez, Aja Sanzone, Kedamawit Tilahun, Chuancang Jiang, V Tse Longping, Kevin W Bock, Mahnaz Minai, Bianca M Nagata, Kenneth Cronin, Victoria Gee-Lai, Margaret Deyton, Maggie Barr, Tarra Von Holle, Andrew N Macintyre, Erica Stover, Jared Feldman, Blake M Hauser, Timothy M Caradonna, Trevor D Scobey, Wes Rountree, Yunfei Wang, M Anthony Moody, Derek W Cain, C Todd DeMarco, Thomas N Denny, Christopher W Woods, Elizabeth W Petzold, Aaron G Schmidt, I-Ting Teng, Tongqing Zhou, Peter D Kwong, John R Mascola, Barney S Graham, Ian N Moore, Robert Seder, Hanne Andersen, Mark G Lewis, David C Montefiori, Gregory D Sempowski, Ralph S Baric, Priyamvada Acharya, Barton F Haynes, Kevin O Saunders
发表日期
2021/8/5
期刊
Cell
卷号
184
期号
16
页码范围
4203-4219. e32
出版商
Cell Press
简介
SARS-CoV-2-neutralizing antibodies (NAbs) protect against COVID-19. A concern regarding SARS-CoV-2 antibodies is whether they mediate disease enhancement. Here, we isolated NAbs against the receptor-binding domain (RBD) or the N-terminal domain (NTD) of SARS-CoV-2 spike from individuals with acute or convalescent SARS-CoV-2 or a history of SARS-CoV infection. Cryo-electron microscopy of RBD and NTD antibodies demonstrated function-specific modes of binding. Select RBD NAbs also demonstrated Fc receptor-γ (FcγR)-mediated enhancement of virus infection in vitro, while five non-neutralizing NTD antibodies mediated FcγR-independent in vitro infection enhancement. However, both types of infection-enhancing antibodies protected from SARS-CoV-2 replication in monkeys and mice. Three of 46 monkeys infused with enhancing antibodies had higher lung inflammation scores compared to …
引用总数